Unfortunately, most manufacturers wait until after a 483 or performance problem to revisit qualification practices. Proactive testing and continued monitoring ensure patient safety and compliance
Dave Rottjakob, Deborah Ensign, Shawn Sherry, and Kate Bloomrose 09.08.14